Table 33.
Occurrence of resistance (%) to selected antimicrobials in indicator Escherichia coli from calves under 1 year of age, using harmonised ECOFFs, 10 EU MSs, 2017
| Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 181 | 0.6 | 6.1 | 8.8 | 1.1 | 0 | 0 | 0 | 2.8 | 3.9 | 0 | 0 | 17.7 | 7.2 | 24.3 |
| Belgium | 185 | 4.9 | 27.6 | 56.8 | 2.7 | 2.2 | 0 | 0 | 10.3 | 20 | 4.3 | 1.1 | 56.2 | 53.5 | 64.9 |
| Croatia | 85 | 1.2 | 5.9 | 14.1 | 0 | 0 | 0 | 0 | 7.1 | 8.2 | 0 | 0 | 31.8 | 8.2 | 31.8 |
| Denmark | 181 | 0.6 | 5.5 | 6.1 | 0.6 | 0.6 | 0 | 0 | 0 | 0 | 0 | 0 | 6.6 | 2.2 | 7.7 |
| France | 200 | 4 | 19 | 44 | 0 | 0 | 0 | 0 | 8 | 9.5 | 7 | 1 | 53 | 33 | 65.5 |
| Germany | 242 | 3.3 | 7.4 | 36 | 2.1 | 2.1 | 0 | 0 | 7 | 9.1 | 5 | 2.5 | 31 | 26.4 | 37.2 |
| Italy | 170 | 13.5 | 31.8 | 63.5 | 5.3 | 5.3 | 0 | 0 | 22.9 | 47.6 | 1.8 | 2.9 | 68.8 | 63.5 | 77.6 |
| Netherlands | 301 | 3.3 | 16.6 | 22.9 | 0 | 0 | 0 | 0 | 3 | 3.7 | 0 | 0 | 29.2 | 21.3 | 47.2 |
| Portugal | 181 | 1.7 | 4.4 | 9.9 | 3.3 | 3.3 | 0 | 0 | 3.3 | 3.3 | 0 | 0 | 13.3 | 7.7 | 23.2 |
| Spain | 167 | 5.4 | 16.8 | 21 | 1.2 | 1.2 | 0 | 0 | 5.4 | 6.6 | 0.6 | 0 | 39.5 | 17.4 | 52.7 |
| Total (10 MSs) | 1893 | 3.9 | 14.4 | 29 | 1.6 | 1.4 | 0 | 0 | 6.7 | 10.6 | 2 | 0.8 | 34.4 | 24.7 | 43.8 |
| Norway | 296 | 0.3 | 0.7 | 1.7 | 0.7 | 0.7 | 0 | 0 | 0 | 0 | 0 | 0 | 4.4 | 0 | 3.4 |
| Switzerland | 194 | 4.6 | 9.8 | 38.7 | 0 | 0 | 0 | 0 | 3.6 | 3.6 | 0 | 0 | 46.9 | 19.1 | 41.2 |
ECOFFs: epidemiological cut‐off values; MSs: Member States; N: number of isolates tested; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.